Literature DB >> 3117395

Metabolism of hexamethylmelamine in mice.

I R Judson, C J Rutty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3117395     DOI： 10.1007/bf00253977

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  5 in total

1.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Authors:  I R Judson; A H Calvert; C J Rutty; G Abel; L A Gumbrell; M A Graham; B D Evans; D E Wilman; S E Ashley; F Cairnduff
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

5.  Variable oral absorption of hexamethylmelamine in man.

Authors:  M D'Incalci; G Bolis; C Mangioni; L Morasca; S Garattini
Journal:  Cancer Treat Rep       Date:  1978-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.